-
Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors.
Zhang MQ,
Gaisser S,
Nur-E-Alam M,
Sheehan LS,
Vousden WA,
Gaitatzis N,
Peck G,
Coates NJ,
Moss SJ,
Radzom M,
Foster TA,
Sheridan RM,
Gregory MA,
Roe SM,
Prodromou C,
Pearl L,
Boyd SM,
Wilkinson B,
Martin CJ.
Biotica Technology Limited, Chesterford Research Park, Nr. Saffron Walden, Essex CB10 1XL, United Kingdom.
A biosynthetic medicinal chemistry approach was applied to the optimization of the natural product Hsp90 inhibitor macbecin. By genetic engineering, mutants have been created to produce novel macbecin analogues including a nonquinone compound (5) that has significantly improved binding affinity to Hsp90 (Kd 3 nM vs 240 nM for macbecin) and reduced toxicity (MTD > or = 250 mg/kg). Structural flexibility may contribute to the preorganization of 5 to exist in solution in the Hsp90-bound conformation.
PMID: 18800759 [PubMed - indexed for MEDLINE]
-
Structures reported by this article